AAV Gene Therapy Vectors for Neurodegenerative Diseases

Migration, Crosslink

📖

AAV Gene Therapy Vectors for Neurodegenerative Diseases

active

wiki page Created: 2026-04-02T07:19:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-aav-cns-gene-therapy

📖 Wiki Page

therapeutic1465 wordssynced 2026-04-02

AAV Gene Therapy Vectors for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">AAV Gene Therapy Vectors for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Route</td>
<td>BBB Crossing</td>
</tr>
<tr>
<td class="label">Intravenous</td>
<td>Requires engineered capsids</td>
</tr>
<tr>
<td class="label">Intrathecal</td>
<td>Direct to CSF</td>
</tr>
<tr>
<td class="label">Intracerebroventricular</td>
<td>Direct to ventricles</td>
</tr>
<tr>
<td class="label">Intraparenchymal</td>
<td>Direct to brain</td>
</tr>
<tr>
<td class="label">Serotype</td>
<td>BBB Crossing</td>
</tr>
<tr>
<td class="label">AAV9</td>
<td>Yes (high)</td>
</tr>
<tr>
<td class="label">AAVrh.10</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">PHP.B / PHP.eB</td>
<td>Yes (mouse-biased)</td>
</tr>
<tr>
<td class="label">AAV2</td>
<td>Limited</td>
</tr>
<tr>
<td class="label">AAV5</td>
<td>Limited</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Focus Programs</td>
</tr>
<tr>
<td class="label">Voyager Therapeutics</td>
<td>PD, AD, ALS</td>
</tr>
<tr>
<td class="label">Passage Bio</td>
<td>HD, AD</td>
</tr>
<tr>
<td class="label">Prevail Therapeutics</td>
<td>ALS, PD</td>
</tr>
<tr>
<td class="label">uniQure</td>
<td>AD, HD</td>
</tr>
<tr>
<td class="label">Spark Therapeutics</td>
<td>Inherite

...

AAV Gene Therapy Vectors for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">AAV Gene Therapy Vectors for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Route</td>
<td>BBB Crossing</td>
</tr>
<tr>
<td class="label">Intravenous</td>
<td>Requires engineered capsids</td>
</tr>
<tr>
<td class="label">Intrathecal</td>
<td>Direct to CSF</td>
</tr>
<tr>
<td class="label">Intracerebroventricular</td>
<td>Direct to ventricles</td>
</tr>
<tr>
<td class="label">Intraparenchymal</td>
<td>Direct to brain</td>
</tr>
<tr>
<td class="label">Serotype</td>
<td>BBB Crossing</td>
</tr>
<tr>
<td class="label">AAV9</td>
<td>Yes (high)</td>
</tr>
<tr>
<td class="label">AAVrh.10</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">PHP.B / PHP.eB</td>
<td>Yes (mouse-biased)</td>
</tr>
<tr>
<td class="label">AAV2</td>
<td>Limited</td>
</tr>
<tr>
<td class="label">AAV5</td>
<td>Limited</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Focus Programs</td>
</tr>
<tr>
<td class="label">Voyager Therapeutics</td>
<td>PD, AD, ALS</td>
</tr>
<tr>
<td class="label">Passage Bio</td>
<td>HD, AD</td>
</tr>
<tr>
<td class="label">Prevail Therapeutics</td>
<td>ALS, PD</td>
</tr>
<tr>
<td class="label">uniQure</td>
<td>AD, HD</td>
</tr>
<tr>
<td class="label">Spark Therapeutics</td>
<td>Inherited retinal disease, CNS</td>
</tr>
<tr>
<td class="label">Product</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Luxturna</td>
<td>Spark/Roche</td>
</tr>
<tr>
<td class="label">Zolgensma</td>
<td>Novartis</td>
</tr>
<tr>
<td class="label">Ryplazim</td>
<td>Takeda</td>
</tr>
<tr>
<td class="label">Elevidys</td>
<td>Sarepta</td>
</tr>
</table>

Adeno-associated virus (AAV) vectors are a leading delivery platform for central nervous system (CNS) gene therapy because they combine relatively low pathogenicity, durable transgene expression, and adaptable tissue tropism.[@wang2019][@daya2008] In neurodegeneration, those properties matter because effective therapy usually depends on getting a therapeutic payload into [neurons](/entities/neurons) and glia across the blood-brain barrier or through direct cerebrospinal fluid delivery.[@wang2019][@foust2009] Recent advances in capsid engineering have dramatically improved BBB crossing efficiency, opening new therapeutic possibilities for neurodegenerative diseases.[@bedbrook2018]

Overview

Mermaid diagram (expand to render)

Adeno-associated virus (AAV) vectors are widely used for CNS gene transfer because they can support long-term expression, can be engineered for cell-type selectivity, and in the case of serotypes such as AAV9 can achieve clinically relevant CNS delivery after systemic administration.[@wang2019][@foust2009]

AAV Vector Biology

Structure

Genome: Single-stranded DNA (~4.7 kb)
Capsid: Icosahedral symmetry with 60 subunits
Serotypes: Numerous naturally occurring and engineered variants
Rep/cap system: Viral replication and capsid genes are removed in therapeutic vectors[@daya2008]

Key Properties

Non-pathogenic: Wild-type AAV is not associated with a clear human disease phenotype
Low immunogenicity: Lower innate pathogenicity than many other viral vectors, though immunity remains a major clinical constraint
Long-term expression: Episomal persistence can support multi-year expression
Integration: Usually episomal rather than integrative, reducing but not eliminating insertional risk
Cell-type specificity: Tropism depends strongly on capsid choice and route of administration[@wang2019]

Payload Capacity

The ~4.7 kb packaging limit constrains cargo size. This necessitates:

Use of small promoters (e.g., synapsin, CBA)
Split-intein systems for larger genes
Focus on loss-of-function (siRNA, miRNA) rather than large gene insertion
CRISPR systems require careful design to fit within payload limits[@ran2016]

CNS Delivery Methods

Direct Brain Injection

Intraparenchymal: Direct injection into target tissue
Intracerebroventricular (ICV): Delivery into the ventricular system
Intrathecal (IT): Delivery into spinal cerebrospinal fluid
Convection-enhanced delivery (CED): Pressure-assisted infusion for broader regional spread[@wang2019]

Systemic Delivery

Intravenous (IV): Requires serotypes or engineered capsids with meaningful BBB transit
Intranasal: Experimental, non-invasive nose-to-brain route
AAV9: The most established clinically relevant CNS serotype for systemic delivery[@foust2009][@hudry2019]

Delivery Route Comparison

Major AAV Serotypes for CNS

Engineered Capsids for Enhanced CNS Delivery

AAV-PHP Variants

The PHP (PHP.B, PHP.eB, PHP.S) family represents a breakthrough in BBB-crossing capsids:

PHP.B: Created via directed evolution, shows high BBB penetration in C57BL/6 mice[@chan2017]
PHP.eB: Enhanced version with improved transduction efficiency
PHP.S: Alternative variant with different tropism profile
Note: Effectiveness varies across species; human translation remains challenging

AAVHSC

Hematopoietic stem cell-derived capsids (AAVHSC) represent another engineering approach:

AAVHSC15 and AAVHSC17: Show improved CNS delivery relative to wild-type
Derived from naturally occurring variants in hematopoietic cells
Currently in preclinical and early clinical development[@bedbrook2018]

AAV.CAP-B10

An engineered capsid with CNS tropism:

Selected for ability to transduce neurons and [astrocytes](/entities/astrocytes)
Shows promise for targeting specific brain regions
Under investigation for Parkinson's and Alzheimer's applications[@ravitz2020]

Clinical Applications in Neurodegeneration

Parkinson's Disease

AAV2-AADC: Aromatic L-amino acid decarboxylase gene transfer to the striatum
AAV2-GAD: Glutamic acid decarboxylase delivery to the subthalamic nucleus
Results: Early trials demonstrated safety and motor signal improvement in advanced Parkinson's disease cohorts[@mittermeyer2012]
Voyager Therapeutics has advanced AAV gene therapy programs for PD using optimized capsids

Alzheimer's Disease

AAV-BDNF: Brain-derived neurotrophic factor delivery
AAV-NGF: Nerve growth factor support for cholinergic systems
Status: Earlier-stage translational work focused on neurotrophic support[@wang2019]
uniQure has explored AAV-mediated BDNF delivery for AD

Amyotrophic Lateral Sclerosis

AAV-SOD1 silencing: Gene-silencing approaches for familial SOD1 ALS
AAV-ATXN2: Lowering modifier targets implicated in motor neuron degeneration
Status: The field remains largely preclinical to early clinical[@wang2019]
Prevail Therapeutics (acquired by Eli Lilly) developed AAV programs for ALS

Huntington's Disease

AAV-[HTT](/proteins/htt-protein) silencing: Mutant [huntingtin](/genes/htt)-lowering strategies
AAV-CRISPR: Gene-editing approaches under active development
Status: AAV5-miHTT and related programs have moved Huntington's into human studies[@tabrizi2022]
Passage Bio has HD gene therapy candidates in development

Clinical Pipeline and Companies

Major Companies in AAV CNS Gene Therapy

Active Clinical Trials

Multiple AAV gene therapy trials are underway:

AAV-AADC for Parkinson's (multiple Phase 1/2 trials)
AAV-GDNF for Parkinson's (early clinical)
AAV-HTT lowering for Huntington's (Phase 1/2)
Various ALS gene therapy programs (SOD1, [C9orf72](/entities/c9orf72) targets)

Manufacturing Challenges

Production yields: CNS programs often require very large vector doses[@wang2019]

Purification: Empty/full capsid separation affects potency and safety

Dosing: Systemic CNS delivery can require extremely high vector genomes per kilogram

Immunogenicity: Pre-existing antibodies and post-dose immune responses complicate eligibility[@mingozzi2013]

Cost: Manufacturing scale and quality control remain major constraints[@wang2019]

Scalability: Triple transfection in HEK293 cells remains the dominant production method

FDA-Approved AAV Gene Therapies

No AAV therapy is yet FDA approved specifically for a CNS neurodegenerative disease, but the platform has demonstrated regulatory viability in related neurologic indications.[@hudry2019]

Safety Considerations

Immune Response

Pre-existing neutralizing antibodies can block vector transduction
T-cell responses against transduced cells may eliminate expression
Steroid pretreatment being explored to mitigate immune responses

Off-Target Effects

Promoter design critical for cell-type specificity
Some serotypes show broader tropism than desired
Dose-dependent toxicity observed at high concentrations

Insertional Risk

AAV integrates at low frequency (relative to gamma-retrovirus)
Clinical data from hemophilia trials shows generally favorable safety[@ngozzi2022]

External Links

[ClinicalTrials.gov](https://clinicaltrials.gov)
[American Society of Gene & Cell Therapy](https://www.asgct.org)

Background

The rapid rise of AAV-based therapeutics reflects converging improvements in capsid engineering, promoter design, neurosurgical delivery, and large-scale vector manufacturing. Those advances have turned CNS gene therapy from a purely experimental strategy into a realistic therapeutic platform for neurodegenerative disease programs.[@wang2019][@bedbrook2018]

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

[Wang D, Tai PWL, Gao G, Adeno-associated virus vector as a platform for gene therapy delivery (2019)](https://doi.org/10.1038/s41573-019-0012-7)

[Daya S, Berns KI, Gene therapy using adeno-associated virus vectors (2008)](https://doi.org/10.1128/CMR.00008-08)

[Foust KD, Nurre E, Montgomery CL, et al, Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes (2009)](https://doi.org/10.1038/nbt.1515)

[Bedbrook CN, Deverman BE, Schaffer DV, AAV Engineering: Advancing Viral Vectors for Gene Therapy (2018)](https://doi.org/10.1016/j.tibtech.2018.04.003)

[Ran H, Gaj T, Zetsche B, et al, Expanding the scope of CRISPR-Cas9 genome editing in human cells using AAV (2016)](https://doi.org/10.1038/nmeth.3852)

[Hudry E, Vandenberghe LH, Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality (2019)](https://doi.org/10.1016/j.neuron.2019.02.017)

[Chan KY, Jang MJ, Yoo BB, et al, Engineered AAVs for efficient retrograde transduction (2017)](https://doi.org/10.1038/s41587-017-0015-9)

[Ravitz J, Kotin R, Capsid engineering for CNS gene therapy (2020)](https://doi.org/10.1016/j.neuron.2020.12.015)

[Mittermeyer G, Christine CW, Rosenbluth KH, et al, Long-term evaluation of AAV2-AADC gene therapy for Parkinson's disease (2012)](https://doi.org/10.1212/WNL.0b013e31826a5a0f)

[Tabrizi SJ, Leavitt BR, Kordasiewicz H, et al, First-in-Human Study of AAV5-miHTT Gene Therapy for Huntington's Disease (2022)](https://doi.org/10.1002/ana.26308)

[Mingozzi F, High KA, Immune responses to AAV vectors: overcoming barriers to successful gene therapy (2013)](https://doi.org/10.1182/blood-2013-01-306647)

[Ngozzi F, Anguela TM, Pavani G, et al, AAV vector-mediated liver gene therapy in hemophilia (2022)](https://doi.org/10.1182/blood-2022-01-775080)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — 0.73 · Target: BDNF
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF
[Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — 0.48 · Target: CHR2/BDNF
[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — 0.71 · Target: P2RY12

Related Analyses:

[CRISPR-based therapeutic approaches for neurodegenerative diseases](/analysis/SDA-2026-04-02-gap-crispr-neurodegeneration-20260402) 🔄
[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-aav-cns-gene-therapy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-aav-cns-gene-therapy
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-50853bad9f7d
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-aav-cns-gene-therapy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

72

Outgoing

119

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

AAV Gene Therapy Vectors for Neurodegenerative Diseases

AAV Gene Therapy Vectors for Neurodegenerative Diseases

Introduction

AAV Gene Therapy Vectors for Neurodegenerative Diseases

Introduction

Overview

AAV Vector Biology

Structure

Key Properties

Payload Capacity

CNS Delivery Methods

Direct Brain Injection

Systemic Delivery

Delivery Route Comparison

Major AAV Serotypes for CNS

Engineered Capsids for Enhanced CNS Delivery

AAV-PHP Variants

AAVHSC

AAV.CAP-B10

Clinical Applications in Neurodegeneration

Parkinson's Disease

Alzheimer's Disease

Amyotrophic Lateral Sclerosis

Huntington's Disease

Clinical Pipeline and Companies

Major Companies in AAV CNS Gene Therapy

Active Clinical Trials

Manufacturing Challenges

FDA-Approved AAV Gene Therapies

Safety Considerations

Immune Response

Off-Target Effects

Insertional Risk

See Also

External Links

Background

Allen Brain Atlas Resources

References

💬 Discussion

📗 Cite This Artifact

AAV Gene Therapy Vectors for Neurodegenerative Diseases

AAV Gene Therapy Vectors for Neurodegenerative Diseases

Introduction

AAV Gene Therapy Vectors for Neurodegenerative Diseases

Introduction

Overview

AAV Vector Biology

Structure

Key Properties

Payload Capacity

CNS Delivery Methods

Direct Brain Injection

Systemic Delivery

Delivery Route Comparison

Major AAV Serotypes for CNS

Engineered Capsids for Enhanced CNS Delivery

AAV-PHP Variants

AAVHSC

AAV.CAP-B10

Clinical Applications in Neurodegeneration

Parkinson's Disease

Alzheimer's Disease

Amyotrophic Lateral Sclerosis

Huntington's Disease

Clinical Pipeline and Companies

Major Companies in AAV CNS Gene Therapy

Active Clinical Trials

Manufacturing Challenges

FDA-Approved AAV Gene Therapies

Safety Considerations

Immune Response

Off-Target Effects

Insertional Risk

See Also

External Links

Background

Allen Brain Atlas Resources

References

Related Hypotheses

💬 Discussion